The stakes are too high for patient safety and keeping your development pipeline productive, let alone maximizing ROI, to risk a poorly executed pharmacokinetics (PK) / toxicokinetics (TK) package in your investigational new drug report (IND). As drug candidates become more complex, regulators have learned how impactful every biological insight can be to approve first-in-human (FIH) testing.
This Webinar report provides a summary of key insights for PK/TK in drug development.
